Clinical Trial

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Study acronym: EmPATH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Recruiting 2026-08-11
Trial Details
NCT Number NCT06992440
Lead Sponsor Gustavo A Heresi, MD, MS
Collaborators: The Cleveland Clinic, National Heart, Lung, and Blood Institute (NHLBI)
Conditions Pulmonary Arterial Hypertension
Enrollment 78 participants
Start Date 2025-06-26
Primary Completion 2030-07 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-13